Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Medical Officer | March 02, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date March 02, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,953 |
Ending reported balance
After 2022-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-02 · Grant · Acquired 8,500 · Balance 95,799 F1: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Row 2 · 2022-03-02 · Sale · Disposed 4,846 · Balance 90,953 F2: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 72,856 |
Reported balance
After 2022-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-02 · Grant · Acquired 72,856 · Balance 72,856 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01 · Expires 2032-03-02 | Direct | 124,644 |
Reported balance
After 2022-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-02 · Grant · Acquired 124,644 · Balance 124,644 F4: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
F2: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
F4: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 124,644 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · derivative · entry 4 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,644 Underlying: Common Stock · 124,644 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 72,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · derivative · entry 3 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,856 Underlying: Common Shares · 72,856 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 4,846 | $12.01 | $58,200.46 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · nonDerivative · entry 2 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,953 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,799 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · derivative · entry 10 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F8 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 100,000 | $28.89 | $2,889,000.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 7 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.50 to $29.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 100,000 | $5.30 | $530,000.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 6 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · derivative · entry 9 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 30,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F8 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · derivative · entry 8 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2029-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F7 · derivative.exercise_date: The shares subject to the option vest in twenty-four equal monthly installments from the grant date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 10,000 | $30.55 | $305,500.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 5 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.30 to $30.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 90,000 | $31.17 | $2,805,300.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 4 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.00 to $31.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 30,000 | $5.30 | $159,000.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 3 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 70,000 | $6.06 | $424,200.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 2 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 50,000 | $30.17 | $1,508,500.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:24 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-021484 · wf-form4_163597106564909.xml · derivative · entry 3 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F4 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:24 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 45,000 | $31.64 | $1,423,800.00 |
DisclosureSEC source: 0001628280-21-021484 · wf-form4_163597106564909.xml · nonDerivative · entry 2 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,299 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $31.50 to $31.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:24 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 45,000 | $5.30 | $238,500.00 |
DisclosureSEC source: 0001628280-21-021484 · wf-form4_163597106564909.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001628280-21-018594 · wf-form4_163165384671882.xml · derivative · entry 3 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Shares | 150,000 | $3.20 | $480,000.00 |
DisclosureSEC source: 0001628280-21-018594 · wf-form4_163165384671882.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 21:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 150,000 | $19.84 | $2,976,000.00 |
DisclosureSEC source: 0001628280-21-018594 · wf-form4_163165384671882.xml · nonDerivative · entry 2 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,299 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.77 to $19.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 20:15 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,000 | $15.85 | $79,250.00 |
DisclosureSEC source: 0001628280-21-017662 · wf-form4_163000892467082.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 28, 2021. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:11 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 45,000 | $16.03 | $721,350.00 |
DisclosureSEC source: 0001628280-21-016407 · wf-form4_162862630456598.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 28, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:36 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001628280-21-004740 · wf-form4_161584054793459.xml · derivative · entry 3 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2021-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:36 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 40,000 | $13.49 | $539,600.00 |
DisclosureSEC source: 0001628280-21-004740 · wf-form4_161584054793459.xml · nonDerivative · entry 2 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,299 F2 · price: The price in column 4 is a weighted average price and were converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the sold date. These shares were sold in multiple transactions ranging from $13.34 to $13.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:36 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 40,000 | $3.02 | $120,800.00 |
DisclosureSEC source: 0001628280-21-004740 · wf-form4_161584054793459.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.